MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

MoonLake Immunotherapeutics Announces Pricing of $400 Million
Upsized Public Offering of Class A Ordinary Shares

ZUG, Switzerland, June 28, 2023 – MoonLake Immunotherapeutics (Nasdaq:MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the pricing on June 27, 2023 of its upsized underwritten public offering of 8,000,000 Class A ordinary shares at a public offering price per share of $50.00. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other offering expenses payable by MoonLake, are expected to be $400 million. In addition, MoonLake has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,200,000 Class A ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 30, 2023, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by MoonLake.

MoonLake intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, to fund the ongoing advancement of Sonelokimab and for general corporate purposes.

SVB Securities, Guggenheim Securities, Cantor and LifeSci Capital are acting as joint bookrunning managers for the offering. BTIG and H.C. Wainwright & Co. are also acting as lead managers for the offering.

A shelf registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on May 9, 2023. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov and may also be obtained, when available, by contacting SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, or by telephone at 212 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, New York 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com; or LifeSci Capital LLC, Attention: Syndicate Prospectus Department, 250 West 55th Street, 34th Floor, New York, NY 10019, by email at compliance@lifescicapital.com or by telephone at (646) 876-5059.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations regarding the consummation of the offering, the anticipated use of the net proceeds of the offering and the satisfaction of customary closing conditions with respect to the offering. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward- looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that the offering will not be consummated; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2022 and other subsequent disclosure documents filed with the SEC.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

MoonLake Immunotherapeutics Investors
Matthias Bodenstedt, CFO
ir@moonlaketx.com

MoonLake Immunotherapeutics Media
Patricia Sousa, Director Corporate Affairs
media@moonlaketx.com

Consilium Strategic Communications
Tel: +44 (0) 20 3709 5700
MoonLake@consilium-comms.com
Mary-Jane Elliott, Ashley Tapp



MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

TIN LIÊN QUAN

Beamr Imaging Ltd. Announces Pricing of Initial Public

Herzeliya, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (Nasdaq: BMR) ('Beamr' or the 'Company'), an innovator of video encoding,...

Results of the Offering of Unsecured Subordinated Bonds of

The public offering of Bigbank AS (hereinafter Bigbank) unsecured subordinated bonds (hereinafter the Offering) ended on Friday, 10 February. It was the...

Rugby Announces CAD$1,000,000 Non-brokered Private

This news release is not for distribution to United States newswire service or for dissemination in the United States Vancouver, B.C., Feb. 10, 2023 ...

THỦ THUẬT HAY

[Chia sẻ] Để có ảnh đẹp trong những ngày Tết

Tết là một trong những dịp mà mọi người chụp ảnh rất nhiều, và để có những bức ảnh đẹp ngày Tết, mình xin post lại chia sẻ của anh Nguyễn Phúc Lộc về một số thủ thuật và lưu ý khi chụp ảnh, cả bằng điện thoại lẫn máy

Hướng dẫn các cách tắt âm thanh khởi động của máy Mac

Dòng máy Mac có một đặc trưng là khi bạn nhấn nút Power để khởi động máy, bạn sẽ nghe thấy một âm thanh phát ra từ máy ngay trước khi logo quả táo và nền trắng xuất hiện. Đây là dấu hiệu cho thấy phần cứng máy Mac của

Làm sao để vô hiệu hóa Hyperlink trong Excel

Khi bạn muốn copy một dòng text nào đó trong Excel, nhưng lại dính phải Hyperlink. Nếu chứa đường link liên kết, khi chúng ta tích vào sẽ truy cập vào trang web đã được chèn. Vậy phải làm như thế nào?

Lời xin lỗi người yêu, bạn gái hay

Nếu như, trong cuộc sống, bạn gây ra những chuyện khiến người mà mình yêu thương phải buồn, phải suy nghĩ, các bạn có thể gửi đến họ một lời xin lỗi để họ có thể nhận ra là bản thân cô ấy quan trọng với bạn như thế

Nhập văn bản bằng giọng nói tiếng Việt chính xác trên iPhone

Sử dụng tính năng hay và tiện lợi có sẵn trên iPhone để soạn văn bản, tin nhắn, gửi mail, tìm kiếm bằng giọng nói tiếng Việt chính xác

ĐÁNH GIÁ NHANH

Hiệu năng và thời lượng pin HTC U11+: Liệu có được như thông số trên giấy?

HTC U11+ đang là chiếc điện thoại cao cấp nhất của HTC. Dù HTC hiện vẫn gặp rất nhiều khó khăn trong kinh doanh nhưng không thể phủ nhận HTC U11+ là một chiếc điện thoại rất chất lượng.

Đánh giá Honda City 2018 về thiết kế vận hành và giá bán mới nhất

Honda City 2018 là dòng xe được ưa chuộng tại Việt Nam, nằm trong phân khúc xe sedan hạng B cạnh tranh với nhiều đối thủ như Toyota Vios, Mazda 2, Kia Rio, Hyundai Accent, Mitsubishi Attrage, Ford Fiesta. Với hai phiên

Đánh giá pin Xiaomi Mi Mix 2: kém hơn thế hệ đầu tiên

Mi Mix 2 thật sự là một sự cải lùi so với Mi Mix thế hệ đầu tiên, ít nhất là ở thời gian sử dụng pin. Với viên pin nhỏ hơn (chỉ 3.400 mAh thay vì 4.400 mAh), thời gian dùng của Mi Mix 2 kém hơn so với đời trước như một